Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.20.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development $ 4,507,784 $ 1,275,948
General and administrative 5,466,654 1,426,056
Total operating expenses 9,974,438 2,702,004
Loss from operations (9,974,438) (2,702,004)
Other (expenses) income:    
Interest/investment income, net 407,652 15,939
Realized loss on short-term investments (171,611)
Unrealized loss on short-term investments (934,919)
Total other (expenses) income (698,878) 15,939
Net loss $ (10,673,316) $ (2,686,065)
Loss per common share – basic and diluted $ (0.72) $ (0.36)
Weighted average number of common shares outstanding – basic and diluted 14,738,230 7,509,493